The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?
Open accessAbstract
&NA; Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin disease characterized by a complex pathophysiology and a wide spectrum of the clinical phenotype. Despite this high degree of heterogeneity, AD is still considered a single disease and usually treated according to the “one‐size‐fits‐all” approach. Thus more tailored prevention and therapeutic strategies are still lacking. As for other disciplines, such as oncology or rheumatology, we have to approach AD in a more differentiated way (ie, to dissect and stratify the complex clinical phenotype into more homogeneous subgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the management of this condition. Because we are now entering the era of personalized medicine, a systems biology approach merging the numerous clinical phenotypes with robust (ie, relevant and validated) biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD. This approach will not only allow an optimized prevention and treatment with the available drugs but also hopefully help assign newly developed medicinal products to those patients who will have the best benefit/risk ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Skin barrier impairment at birth predicts food allergy at 2 years of age
Kelleher, M. M., Dunn-Galvin, A., Gray, C., Murray, D. M., Kiely, M., Kenny, L., McLean, W. H. I., Irvine, A. D., & Hourihane, J. O. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1312 · Cited by 169
RetractedBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.636 · Cited by 5,615 · cited 1×
“Endophenotypes are defined asmeasurable components unseen by the unaided eye along the pathway between disease and distal genotype.(38) Thus the endophenotype is made of a collection of biomarkers between the clinical phenotype and genotype.”
BackgroundWilliams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,596
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWeidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
EAACI Molecular Allergology User's Guide
Matricardi, P. M., Kleine‐Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer‐Weber, B., et al. (2016) · Pediatric Allergy and Immunology · doi:10.1111/pai.12563 · Cited by 932
Self-citationEmollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Simpson, E. L., Chalmers, J. R., Hanifin, J. M., Thomas, K. S., Cork, M. J., McLean, W. H. I., Brown, S. J., Chen, Z., Chen, Y., & Williams, H. C. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.005 · Cited by 722
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Self-citationAtopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Self-citationSignificance of Skin Barrier Dysfunction in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. M. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.3.207 · Cited by 393
Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343
Self-citation
Metadata
- Authors
- Bieber, T., D'Erme, A. M., Akdis, C. A., Traidl-Hoffmann, C., Lauener, R., Schäppi, G., & Schmid-Grendelmeier, P.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 139
- Issue
- 4
- Pages
- S58-S64
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2604249065
- Cited by
- 330
- References
- 71
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? https://app.cochat.ai/papers/10.1016/j.jaci.2017.01.008
- The paper
- Bieber, T., D'Erme, A. M., Akdis, C. A., Traidl-Hoffmann, C., Lauener, R., Schäppi, G., & Schmid-Grendelmeier, P. (2017). Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2017.01.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.